Travere Therapeutics And CSL Vifor Announce EMA Has Accepted For Review The Conditional Marketing Authorization Application For Sparsentan For The Treatment Of IgA Nephropathy
Travere Therapeutics, Inc. (NASDAQ:TVTX) and CSL Vifor today announced that the EMA has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment of IgAN, a rare